Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 2,633–2,640 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Merck & Company Inc. LAGEVRIO - (Molnupiravir) COVID-19 Phase 3 oral COVID-19
Merck & Company Inc. V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002) Personalized cancer vaccine, high-risk melanoma, lung cancer Phase 3 Data Released Intravenous Oncology
Merck & Company Inc. KEYTRUDA (pembrolizumab) - KN-604 Small cell lung cancer (SCLC) Phase 3 Intravenous Oncology
Merck & Company Inc. KEYTRUDA (pembrolizumab) Triple negative breast cancer (TNBC) Phase 3 Intravenous Oncology
Merck & Company Inc. KEYTRUDA (pembrolizumab) - KN-240 Hepatocellular Carcinoma Phase 3 Intravenous Oncology
Merck & Company Inc. KEYTRUDA (pembrolizumab) KN-062 Gastric cancer Phase 3 Intravenous Oncology
Merck & Company Inc. Rezafungin (CD101) ReSPECT Prophylaxis Phase 3 Intravenous N/A
Merck & Company Inc. LYNPARZA (olaparib) - (OlympiA) Early Breast Cancer Phase 3 Data Released oral Oncology